...
首页> 外文期刊>Archives of virology >Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus
【24h】

Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus

机译:NKT细胞激动剂α-半乳糖基胺的佐剂使用导致M2的DNA疫苗免疫原性和免受流感病毒的保护性免疫力的增强

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

DNA vaccines can induce both humoral and cellular immune responses in animals. However, DNA vaccines suffer from limited vaccine potency due to low immunogenicity. Therefore, different strategies are required for significant improvement of DNA vaccine efficacy such as inclusion of strong adjuvants. The aim of the present study was to investigate the effects of using alpha-Galactosylceramide (alpha-GalCer) as an adjuvant to enhance the immune responses induced by a DNA vaccine, encoding influenza A virus matrix protein 2 (M2), against influenza A challenge. BALB/c mice were immunized three times by intramuscular inoculations of DNA vaccine encoding M2 alone or in combination with alpha-GalCer adjuvant. The adjuvant effect was evaluated by measuring the serum antibody titers, using ELISA, lymphocyte proliferation, using MTT assay as well as Th1 (IFN-gamma and IL-12) and Th2 (IL-4) cytokines. The results showed that co-administration of alpha-GalCer with the vaccine exert protective effects by influencing the magnitude and quality of humoral responses. Adjuvanted DNA-vaccinated mice revealed a higher IgG titer and IgG2a/IgG1 ratio than mice vaccinated with DNA alone. Furthermore, analysis of M2-specific responses revealed that the DNA vaccine triggered predominately IgG1 and IL-4 responses indicating a Th2 bias. The data also showed that alpha-GalCer is a potent adjuvant for activation of cellular immune responses to DNA vaccine. This was supported by a higher IgG2a/IgG1 ratio, significantly increased IFN-gamma and IL-4 production and CD4+ proliferation, compared with mice receiving the DNA vaccine alone, suggesting a mixed Th1/Th2-type cellular immune response with a Th1 bias. The findings of this study indicate that alpha-GalCer has the potential to be used as a potent adjuvant for a DNA vaccine encoding M2, since it enhances humoral and cellular immune response and improves immune protection against influenza challenge in mice.
机译:DNA疫苗可诱导动物中的体液和细胞免疫应答。然而,由于低免疫原性,DNA疫苗受疫苗效力有限。因此,需要不同的策略来显着改善DNA疫苗疗效,例如包含强佐剂。本研究的目的是调查使用α-半乳糖苷(α-神经酰胺)作为佐剂,以增强由DNA疫苗诱导的免疫应答的影响,编码A型流感病毒基质蛋白2(M2),对流感的挑战。通过单独编码M2的DNA疫苗或与α-高压糖佐剂组合的DNA疫苗进行三次,将BALB / C小鼠免疫三次。通过使用ELISA,淋巴细胞增殖,使用MTT测定以及TH1(IFN-Gamma和IL-12)和TH2(IL-4)细胞因子来评估佐剂效果。结果表明,通过影响体液反应的幅度和质量,共同施用α-高层疫苗施加保护作用。佐剂的DNA接种疫苗的小鼠揭示了与单独用DNA接种接种的小鼠的更高IgG滴度和IgG2A / IgG1比。此外,M2特异性响应的分析显示DNA疫苗主要引发IgG1和IL-4反应,表明Th2偏压。该数据还表明,α-高级剂是一种有效的佐剂,用于激活对DNA疫苗的细胞免疫应答。与单独接受DNA疫苗的小鼠相比,这是通过较高的IgG2a / IgG1比率,显着增加的IFN-γ和IL-4产生和CD4 +增殖。该研究的发现表明,α-高层的潜力能够用作编码M2的DNA疫苗的有效佐剂,因为它增强了体液和细胞免疫应答,并改善了小鼠对小鼠的甲型流感攻击的免疫保护。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号